Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Share-based Compensation (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed Share-based Compensation for 3 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 44.42% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 0.82% year-over-year, with the annual reading at $4.0 million for FY2025, 0.84% down from the prior year.
  • Share-based Compensation hit $1.2 million in Q4 2025 for Camp4 Therapeutics, up from $984000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.6 million in Q3 2024 to a low of $636000.0 in Q4 2023.
  • Historically, Share-based Compensation has averaged $938700.0 across 3 years, with a median of $858500.0 in 2024.
  • Biggest five-year swings in Share-based Compensation: soared 120.5% in 2024 and later plummeted 38.19% in 2025.
  • Year by year, Share-based Compensation stood at $636000.0 in 2023, then rose by 25.31% to $797000.0 in 2024, then surged by 44.42% to $1.2 million in 2025.
  • Business Quant data shows Share-based Compensation for CAMP at $1.2 million in Q4 2025, $984000.0 in Q3 2025, and $1.0 million in Q2 2025.